Ameriprise Financial Inc. lifted its position in Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 64.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,269 shares of the company’s stock after acquiring an additional 19,300 shares during the period. Ameriprise Financial Inc. owned approximately 0.19% of Dova Pharmaceuticals worth $1,196,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the stock. Laurion Capital Management LP bought a new position in shares of Dova Pharmaceuticals during the 2nd quarter worth approximately $223,000. Bank of New York Mellon Corp bought a new position in shares of Dova Pharmaceuticals during the 3rd quarter worth approximately $340,000. JPMorgan Chase & Co. bought a new position in shares of Dova Pharmaceuticals in the second quarter valued at $382,000. Vanguard Group Inc. bought a new position in shares of Dova Pharmaceuticals in the second quarter valued at $390,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of Dova Pharmaceuticals in the second quarter valued at $493,000. Institutional investors and hedge funds own 26.20% of the company’s stock.
A number of equities analysts have commented on the stock. BidaskClub raised shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, January 13th. Jefferies Group lifted their target price on Dova Pharmaceuticals to $33.00 and gave the stock a “buy” rating in a report on Tuesday, November 28th. Zacks Investment Research raised Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a report on Wednesday, October 11th. Finally, Leerink Swann raised Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 target price for the company in a report on Tuesday, September 26th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Dova Pharmaceuticals has a consensus rating of “Buy” and an average price target of $32.75.
Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.08). During the same period in the prior year, the company posted ($0.41) earnings per share. equities research analysts expect that Dova Pharmaceuticals Inc will post -1.51 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first published by BBNS and is owned by of BBNS. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/dova-pharmaceuticals-inc-dova-shares-bought-by-ameriprise-financial-inc/1824496.html.
Dova Pharmaceuticals Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.